{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:34:54Z","timestamp":1793450094963,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011191","name":"Kunming Institute of Zoology, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1804100"],"award-info":[{"award-number":["2025ZD1804100"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277131"],"award-info":[{"award-number":["22277131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471599"],"award-info":[{"award-number":["82471599"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114695","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:29:42Z","timestamp":1770424182000},"page":"114695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release"],"prefix":"10.1016","volume":"392","author":[{"given":"Chuanjie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bige","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jconrel.2026.114695_bb0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrd.2017.226","article-title":"Drug development in the era of precision medicine","volume":"17","author":"Dugger","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114695_bb0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114695_bb0020","first-page":"1494","article-title":"Past, present and future of drug conjugates for cancer therapy","volume":"6","author":"Cazzamalli","year":"2025","journal-title":"Nat. Can."},{"issue":"22","key":"10.1016\/j.jconrel.2026.114695_bb0025","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody\u2013drug conjugates and small molecule\u2013drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114695_bb0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114695_bb0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114695_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114695_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114695_bb0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114695_bb0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41557-024-01507-y","article-title":"Homogeneous multi-payload antibody\u2013drug conjugates","volume":"16","author":"Journeaux","year":"2024","journal-title":"Nat. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114695_bb0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114695_bb0070","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-\u03b1 targeting: first in-human results","volume":"17","author":"van Dam","year":"2011","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.jconrel.2026.114695_bb0075","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer selective target degradation by folate-caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114695_bb0080","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1021\/acs.jmedchem.5c00226","article-title":"PSMA-guided PROTAC degraders for tumor-specific protein degradation in prostate cancer","volume":"68","author":"Meng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0085","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114695_bb0090","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.jconrel.2026.114695_bb0095","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd4519","article-title":"Principles in the design of ligand-targeted cancer therapeutics and imaging agents","volume":"14","author":"Srinivasarao","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.3c01049","article-title":"Small molecule\u2013drug conjugates emerge as a new promising approach for cancer treatment","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114695_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300720","article-title":"Small molecule-drug conjugates: opportunities for the development of targeted anticancer drugs","volume":"19","author":"Zhang","year":"2024","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114695_bb0115","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220859","article-title":"177Lu\u2013prostate-specific membrane antigen Radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"306","author":"Parihar","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2026.114695_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104946","article-title":"Advancements in folate receptor targeting for anti-cancer therapy: a small molecule-drug conjugate approach","volume":"112","author":"Rana","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114695_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.01.010","article-title":"A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD\/Doxil\/Caelyx) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)","volume":"137","author":"Oza","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jconrel.2026.114695_bb0130","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2021.39.15_suppl.3077","article-title":"Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate targeting FR\u03b1 and TRPV6, in patients with advanced solid tumors","volume":"39","author":"Gong","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jconrel.2026.114695_bb0135","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2020.38.15_suppl.3515","article-title":"Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: phase I and expansion cohort results","volume":"38","author":"Falchook","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jconrel.2026.114695_bb0140","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1200\/jco.2015.33.15_suppl.e13527","article-title":"Phase 1 study of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"33","author":"Ejadi","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114695_bb0145","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4155\/tde.12.99","article-title":"Multivalent ligand: design principle for targeted therapeutic delivery approach","volume":"3","author":"Chittasupho","year":"2012","journal-title":"Ther. Deliv."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114695_bb0150","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","article-title":"High affinity and FAP-targeted radiotracers: a potential design strategy to improve the pharmacokinetics and tumor uptake for FAP inhibitors","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.jconrel.2026.114695_bb0155","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1021\/acs.jmedchem.1c01365","article-title":"Development of asialoglycoprotein-mediated hepatocyte-targeting antitumor prodrugs triggered by glutathione","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114695_bb0160","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1021\/jm1005868","article-title":"Novel octreotide Dicarba-analogues with high affinity and different selectivity for somatostatin receptors","volume":"53","author":"Di Cianni","year":"2010","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.jconrel.2026.114695_bb0165","doi-asserted-by":"crossref","first-page":"15473","DOI":"10.1021\/acs.jmedchem.2c01423","article-title":"Enhancing the safety and efficacy of PSMA-based small-molecule drug conjugates by linker stabilization and conjugation to transthyretin binding ligand","volume":"65","author":"Amin","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114695_bb0170","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.110.175109","article-title":"Reducing undesirable hepatic clearance of a tumor-targeted Vinca alkaloid via novel Saccharopeptidic modifications","volume":"336","author":"Leamon","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114695_bb0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/bc2005522","article-title":"Engineering folate\u2013drug conjugates to target cancer: from chemistry to clinic","volume":"23","author":"Vlahov","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114695_bb0180","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"516","key":"10.1016\/j.jconrel.2026.114695_bb0185","first-page":"1","article-title":"Targeted protein degradation for cancer therapy","volume":"493","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114695_bb0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0006-291X(71)90462-1","article-title":"Hepatic uptake of proteins coupled to fetuin glycopeptide","volume":"45","author":"Rogers","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.114695_bb0195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2024.08.044","article-title":"Liver-targeting chimeras as a potential modality for the treatment of liver diseases","volume":"374","author":"Chen","year":"2024","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.jconrel.2026.114695_bb0200","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.7150\/thno.113852","article-title":"Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114695_bb0205","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114695_bb0210","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jconrel.2026.114695_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113738","article-title":"Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity","volume":"382","author":"Lee","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114695_bb0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C7ME00093F","article-title":"Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy","volume":"3","author":"Khera","year":"2018","journal-title":"Mol. Syst. Des. Eng."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114695_bb0225","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4172\/2157-7439.1000519","article-title":"Advances in delivery systems for doxorubicin","volume":"9","author":"Zhao","year":"2018","journal-title":"J. Nanomed. Nanotechnol."},{"issue":"25","key":"10.1016\/j.jconrel.2026.114695_bb0230","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114695_bb0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/jacs.5c11564","article-title":"A versatile bioorthogonal theranostic platform enables relay activation of tumor cell imaging and targeted protein degradation","volume":"148","author":"Sun","year":"2026","journal-title":"J. Am. Chem. Soc."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:33:29Z","timestamp":1787128409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926000970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"alternative-id":["S0168365926000970"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114695","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114695"}}